Author

Tian‐Xin Hu

Observed names: HU TIANXIN, Tianxin Hu, Tianxin Hu Hu

Institution: Hua Medicine (China)

Observed institution: Hua Medicine (China)

OpenAlex ID: A5112371964

Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

2018 · Dalong Zhu, Shenglian Gan, et al. · The Lancet Diabetes & Endocrinology · 96

Dorzagliatin (HMS5552), a novel dual‐acting glucokinase activator, improves glycaemic control and pancreatic β‐cell function in patients with type 2 diabetes: A 28‐day treatment study using biomarker‐guided patient selection

2018 · Xiao‐Xue Zhu, Da‐Long Zhu, et al. · Diabetes Obesity and Metabolism · 62

Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study

2016 · Lei Sheng, Hongrong Xu, et al. · Drug Design Development and Therapy · 31

Pharmacodynamics Post-Hoc Analysis of Glucose Kinase Activator Dorzagliatin (HMS5552)—Twelve Weeks Treatment in T2D Patients in China

2018 · DALONG ZHU, YU ZHAO, et al. · Diabetes · 4

Works count: 4

Citation count: 193

H-index: 4

I10-index: 3